Source comparison
BPC-157 VEGFR2 Mechanism: Research Comparison
Rat gastric ulcer (Journal of Physiology and Pharmacology, 2020) 10 µg/kg daily, 7 days 2.6-fold increase at Y1175 63% reduction in ulcer area vs 22% control VEGF-A inhibitor (SU5416) blocked BPC-157 effect BPC-157 requires functional VEGFR2 signaling. Blockin
This comparison does not assign a generated winner or score.
- Rat gastric ulcer (Journal of Physiology and Pharmacology, 2020)
- 10 µg/kg daily, 7 days
- 2.6-fold increase at Y1175
- 63% reduction in ulcer area vs 22% control
- VEGF-A inhibitor (SU5416) blocked BPC-157 effect
- BPC-157 requires functional VEGFR2 signaling. Blocking the receptor eliminates therapeutic effect
- Human umbilical vein endothelial cells (Frontiers in Pharmacology, 2018)
- 1 µg/mL, 24-hour exposure
- 2.8-fold increase at Y1175, 1.9-fold at Y1214
- 4.2× increase in tubule formation vs baseline
- VEGF-A (50 ng/mL) produced 5.1× increase
- BPC-157 approaches but doesn't fully match VEGF-A potency at equimolar concentrations in vitro
- Rat Achilles tendon transection (Journal of Orthopaedic Research, 2019)
- 10 µg/kg daily, 14 days
- VEGFR2 expression increased 3.1-fold in repair tissue
- 42% increase in capillary density, 28% increase in tensile strength
- Saline control showed 18% capillary density increase
- BPC-157 drives functional angiogenesis. Not just vessel number but mechanical tissue recovery
- Rat skeletal muscle ischemia (Vascular Pharmacology, 2021)
- 10 µg/kg daily, 10 days
- Sustained phosphorylation >6 hours post-injection
- Blood flow recovery 76% of contralateral limb vs 41% control
- VEGF-A expression unchanged between groups
- BPC-157 restores perfusion without elevating endogenous VEGF-A. Direct receptor activation confirmed